Literature DB >> 18408414

Dihydroartemisinin potentiates the cytotoxic effect of temozolomide in rat C6 glioma cells.

Xiao-Jia Huang1, Cheng-Tan Li, Wei-Ping Zhang, Yun-Bi Lu, San-Hua Fang, Er-Qing Wei.   

Abstract

Gliomas are the most common primary brain tumor in adults, but the efficacy of chemotherapy is limited. Artemisinin and its analogs, such as dihydroartemisinin (DHA), can kill cancer cells via generating free radicals. In the present study, we determined whether DHA at low concentrations potentiates the cytotoxic effect of temozolomide in rat glioma C6 cells. We found that the IC50 values of DHA and temozolomide for cell viability were 23.4 and 560 micromol/l, respectively. The cytotoxic effect of temozolomide was enhanced by 177% at a nontoxic DHA concentration (1 micromol/l), and by 321% at a low-toxic DHA concentration (5 micromol/l). DHA substantially increased temozolomide-induced apoptosis and necrosis. The generation of intracellular reactive oxygen species (ROS) was increased by temozolomide combined with DHA at noneffective concentrations of both agents. Edaravone (20 micromol/l), a ROS scavenger, reversed the effects of temozolomide/DHA on both ROS generation and cell viability reduction. These results indicate that DHA at low concentrations potentiates the cytotoxic effects of temozolomide in C6 cells partly via generating ROS, suggesting a beneficial combination for the chemotherapy of gliomas. Copyright 2008 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18408414     DOI: 10.1159/000125673

Source DB:  PubMed          Journal:  Pharmacology        ISSN: 0031-7012            Impact factor:   2.547


  19 in total

1.  Dihydroartemisinin increases temozolomide efficacy in glioma cells by inducing autophagy.

Authors:  Ze-Shun Zhang; Jing Wang; You-Bi Shen; Cheng-Cheng Guo; K E Sai; Fu-Rong Chen; Xin Mei; F U Han; Zhong-Ping Chen
Journal:  Oncol Lett       Date:  2015-05-06       Impact factor: 2.967

2.  Enhancement of temozolomide-induced apoptosis by valproic acid in human glioma cell lines through redox regulation.

Authors:  Ching-Hsein Chen; Yu-Jia Chang; Maurice S B Ku; King-Thom Chung; Jen-Tsung Yang
Journal:  J Mol Med (Berl)       Date:  2011-02-23       Impact factor: 4.599

3.  Dihydroartemisinin inhibits the Raf/ERK/MEK and PI3K/AKT pathways in glioma cells.

Authors:  Wei DU; Changhe Pang; Yake Xue; Qingjun Zhang; Xinting Wei
Journal:  Oncol Lett       Date:  2015-09-15       Impact factor: 2.967

Review 4.  Development of artemisinin compounds for cancer treatment.

Authors:  Henry C Lai; Narendra P Singh; Tomikazu Sasaki
Journal:  Invest New Drugs       Date:  2012-08-31       Impact factor: 3.850

5.  Delivery of temozolomide to the tumor bed via biodegradable gel matrices in a novel model of intracranial glioma with resection.

Authors:  Umar Akbar; Terreia Jones; Jon Winestone; Madison Michael; Atul Shukla; Yichun Sun; Christopher Duntsch
Journal:  J Neurooncol       Date:  2009-04-01       Impact factor: 4.130

6.  Accumulation of artemisinin trioxane derivatives within neutral lipids of Plasmodium falciparum malaria parasites is endoperoxide-dependent.

Authors:  Carmony L Hartwig; Andrew S Rosenthal; John D'Angelo; Carol E Griffin; Gary H Posner; Roland A Cooper
Journal:  Biochem Pharmacol       Date:  2008-10-19       Impact factor: 5.858

Review 7.  Towards a unifying, systems biology understanding of large-scale cellular death and destruction caused by poorly liganded iron: Parkinson's, Huntington's, Alzheimer's, prions, bactericides, chemical toxicology and others as examples.

Authors:  Douglas B Kell
Journal:  Arch Toxicol       Date:  2010-08-17       Impact factor: 5.153

Review 8.  Terpenoids' anti-cancer effects: focus on autophagy.

Authors:  Chirine El-Baba; Amro Baassiri; Georges Kiriako; Batoul Dia; Sukayna Fadlallah; Sara Moodad; Nadine Darwiche
Journal:  Apoptosis       Date:  2021-07-16       Impact factor: 4.677

9.  Early Chk1 phosphorylation is driven by temozolomide-induced, DNA double strand break- and mismatch repair-independent DNA damage.

Authors:  Motokazu Ito; Shigeo Ohba; Karin Gaensler; Sabrina M Ronen; Joydeep Mukherjee; Russell O Pieper
Journal:  PLoS One       Date:  2013-05-07       Impact factor: 3.240

10.  Anti-cancer drugs elicit re-expression of UDP-glucuronosyltransferases in melanoma cells.

Authors:  Ryan W Dellinger; Harry H Matundan; Amelia S Ahmed; Priscilla H Duong; Frank L Meyskens
Journal:  PLoS One       Date:  2012-10-22       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.